Background & Aims Seroclearance of hepatitis B surface antigen (HBsAg) is a marker for
clearance of chronic hepatitis B virus (HBV) infection, but reported annual incidence rates of …

… Author links open overlay panel Maria Buti 1 2 , Mar Riveiro-Barciela 1 , Rafael Esteban 1
2 … Maria Buti and Mar Riveiro-Barciela have received research grants from Gilead Sciences …

Background & Aims To eliminate hepatitis B virus (HBV) infection, scale-up of testing and
treatment in resource-limited countries is crucial. However, access to nucleic acid testing to …

Hepatitis E virus (HEV) is responsible for a small number of acute hepatitis in developed
countries. In this setting, HEV infection seems to be a zoonosis, although this has not been …

Background & Aims Although EASL guidelines recommend anti-HDV testing in all HBsAg-positive
individuals, HDV infection remains an underdiagnosed condition. We describe the …

Background & Aims In phase 3 trials and real-world settings, smaller proportions of patients
with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic …

Background Long-term incidences and baseline determinants of functional cure (hepatitis B
surface antigen [HBsAg] seroclearance) during entecavir (ETV) or tenofovir disoproxil …

… Mar Riveiro-Barciela has served as speaker for Gilead and MSD and has received grants
from Gilead. Sabela Lens has received speaker/advisory fees from Abbvie, Gilead, Janssen …

Background Long-term antiviral therapy has resulted in viral suppression and biochemical
response in chronic hepatitis B, although the risk of hepatocellular carcinoma has not been …

Background Chronic hepatitis delta is a severe liver disease with rapid progression to
cirrhosis. The impact of hepatitis delta virus (HDV)‐RNA on disease progression and interferon …